A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy.

Trial Profile

A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Leuprorelin (Primary) ; Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms STAND
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results from NCT01431391, NCT01981122 and NCT01487863 studies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top